REG - Truetide PLC - Further re: Sale of interest in Kirkstall Limited
16/10/2025 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251016:nRSP5697Da&default-theme=true
RNS Number : 5697D Truetide PLC 16 October 2025
16 October 2025
Truetide plc
("Truetide" or the "Company")
Further Re: Sale of interest in Kirkstall Limited
Truetide plc (AIM: TRUE), the AIM-listed investment company, provides an
update following its announcement on 14 October 2025 regarding the sale of the
Company's interest in Kirkstall Limited ("Kirkstall") to Imaging Biometrics
Limited ("IBAI"). IBAI is a Jersey-registered company in which Truetide
currently holds a 29.35% interest.
On 15 October 2025, the Company entered into a variation to the sales and
purchase agreement with IBAI in relation to the sale of the shares in
Kirkstall, pursuant to which Truetide has agreed to write off all loan
balances previously owed by Kirkstall to Truetide, totalling £220,853.67, of
which £28,500 was owed to The Ridings Early Growth Investment Company
Limited, a subsidiary of the Company.
The loans had been written down to zero by Truetide in its most recent
accounts for the year ended 31 March 2025 as a prudent assessment of their
current value, since the business was loss making and unlikely to make any
repayments in the reasonably foreseeable future. As these loans had already
been written down to zero in the Company's accounts for the year ended 31
March 2025, this variation has no additional financial impact on Truetide.
For further information:
Truetide plc Tel: 01738 587555
Trevor Brown, Chief Executive Officer
Viv Hallam, Executive Director
Allenby Capital Limited (Nominated Adviser and Joint Broker) Tel: 020 3328 5656
James Reeve / Ashur Joseph
Peterhouse Capital Limited (Joint Broker) Tel: 020 7469 0936
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END FURUVRRRVWURAUA
Copyright 2019 Regulatory News Service, all rights reserved